The OA Trial Bank initiates meta-analyses on predefined subgroups of osteoarthritis (OA) patients from existing studies. Based on the small to moderate effectiveness of the wide range of symptomatic treatments in OA, and the heterogeneity of OA patients, treatment guidelines for OA have stressed the need for research on clinical predictors of response to different treatments.


Identifying responsive subgroups is not simple and it is essential to use the correct methodology in order to avoid that some patients are erroneously deprived of certain treatments, or are erroneously assumed to have an (better) effect from such treatment.


A meta‐analysis for quantifying interaction effects using Individual Patient Data (IPD) is considered to be the gold standard for subgroup analysis. 


This method requires re‐analysis of individual patient data, made available by the authors of the separate trials. Consequently, well‐designed collaborative projects can be initiated.


The OA Trial Bank, the initiator of these subgroup analyses, is formalized with a chair, a Steering Committee and an Executive Coordinator. 

The OA Trial Bank is an initiative officially endorsed by the OARSI and EULAR, and funded by Reumafonds (the Dutch Arthritis Foundation).